Clinical trial
Cytarabine and Clofarabine in Treating Patients With Refractory or Relapsed…
NCT00295841 · Wake Forest University Health Sciences, Other · Completed
Key facts
| NCT number | NCT00295841 |
|---|---|
| Title | Cytarabine and Clofarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia |
| Official title | A Phase I Open-Label Study of High-Dose Cytarabine and Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Refractory or Relapsed Acute Lymphoblastic Leukemia |
| Lead sponsor | Wake Forest University Health Sciences, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Drug |
| Interventions | clofarabine, cytarabine |
| Enrollment | 53 |
| Start date | Feb 1, 2005 |
| Primary completion | Jan 7, 2015 |
| Completion | Jan 7, 2015 |
| First posted | Feb 24, 2006 |
| Last update posted | Aug 10, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: